Article Sidebar

PDF
Issue: Vol. 51 No. 8 (2026): JOURNAL OF MILITARY PHARMACO-MEDICINE No.8 - 2026
Section: Articles
DOI: 10.56535/jmpm.v51i8.2042
Date Published: 28/08/2026
Views 26
Downloads 8
How to Cite
Tran, T. P. T., Nguyen, H. T., & Nguyen, T. S. (2026). ANALYSIS OF FACTORS ASSOCIATED WITH PLASMA BETA-CROSSLAPS LEVELS IN POSTMENOPAUSAL WOMEN WITH OSTEOPOROSIS. Journal of Military Pharmaco-medicine, 51(8), 118-125. https://doi.org/10.56535/jmpm.v51i8.2042

ANALYSIS OF FACTORS ASSOCIATED WITH PLASMA BETA-CROSSLAPS LEVELS IN POSTMENOPAUSAL WOMEN WITH OSTEOPOROSIS

Thi Phuong Thao Tran1, Huy Thong Nguyen1, Tien Son Nguyen1,
1 Military Hospital 103

Main Article Content

Abstract

Objectives: To investigate plasma β-CTX levels and explore the correlation between plasma β-CTX levels and clinical, paraclinical, and treatment characteristics in postmenopausal women with osteoporosis. Methods: A cross-sectional descriptive study was conducted on 70 patients with osteoporosis at Military Hospital 103 from August 2025 to January 2026. Plasma β-CTX levels were quantified, and their associations with clinical factors and bone mineral density (BMD) were analysed. Results: The median plasma β-CTX level was 344.25 pg/mL. Plasma β-CTX levels in the treated group were significantly lower than those in the untreated group (306.90 vs. 628.00 pg/mL; p = 0.002). In patients with acute back pain, plasma β-CTX levels were significantly higher compared to those with chronic pain (754.80 vs. 274.20 pg/mL; p < 0.001). No statistically significant differences in plasma β-CTX levels were observed across different age groups or duration of menopause (p > 0.05). There was no correlation between plasma β-CTX levels and BMD or T-scores (p > 0.05). Conclusion: In postmenopausal osteoporotic women, median plasma β-CTX levels were 344.25 pg/mL, which were lower in those receiving anti-resorptive treatment compared to untreated patients, and higher in those with acute low back pain symptoms compared to those with chronic symptoms.

Keywords

Plasma β-CTX levels, Osteoporosis, Postmenopausal women, Bone mineral density, Bone turnover markers

Article Details

References

1. Alessandro Terreni, Paola Pezzat. Biochemical markers in the follow-up of the osteoporotic patients. Clin Cases Miner Bone Metab. 2012; 9(2):80-84.
2. Harjit Pal Bhattoa, Samuel Vasikaran, Ioulia Trifonidi, et al. Update on the role of bone turnover markers in the diagnosis and management of osteoporosis: A consensus paper from The European Society for Clinical and Economic Aspects of Osteoporosis, Osteoarthritis and Musculoskeletal Diseases (ESCEO), International Osteoporosis Foundation (IOF), and International Federation of Clinical Chemistry and Laboratory Medicine (IFCC). Osteoporos Int. 2025; 36:579-608.
3. Pauline MC, Steven MP, Neil B, et al. American Association of Clinical Endocrinologists and american college of endocrinology clinical practice guidelines for the diagnosis and treatment of postmenopausal osteoporosis. Endocrine practice; 2016; 22 (Suppl 4).
4. Jovanka Novakovic-Paro, Tijana Icin, Milena Mitrovic, et al. Bone turnover markers in women with postmenopausal osteoporosis depending on the level of vitamin D. Endocrine Abstracts. 2016; 41:EP109.
5. Bauer DC, Black DM, Garnero P, et al. Change in bone turnover and hip, non-spine, and vertebral fracture in alendronate-treated women: The fracture intervention trial. J Bone Miner Res. 2004; 19:1250-1258.
6. M Schini, T Vilaca, F Gossiel, et al. Bone turnover markers: Basic biology to clinical applications. Endocr. Rev. 2022; 44(3):417.
7. S Vasikaran, et al. International Osteoporosis Foundation and International Federation of Clinical Chemistry and Laboratory Medicine position on bone marker standards in osteoporosis. Clin. Chem. Lab. Med. 2011; 49(8):1271-1274.
8. TT Hlaing and JE Compston. Biochemical markers of bone turnover - uses and limitations. Royal Society of Medicine Press Ltd. 2014.
9. K Naylor and R Eastel. Bone turnover markers: Use in osteoporosis. Nat. Rev. Rheumatol. 2012; 8(7):379-389.